| Martelli, Maurizio |
TRIANGLE, NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma |
|
|
| Recruiting | 3 | 870 | Europe | R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance) | Prof. Dr. M. Dreyling (co-chairman), LMU Klinikum | Mantle Cell Lymphoma | 05/21 | 05/26 | | |
|
| Recruiting | 3 | 414 | Europe | Gemtuzumab Ozogamicin | Gruppo Italiano Malattie EMatologiche dell'Adulto, Fondazione GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Franco Mandelli Onlus, Pfizer S.R.L. | Acute Myeloid Leukemia | 04/25 | 04/27 | | |
KRdvsRd, NCT04096066: A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant |
|
|
| Active, not recruiting | 3 | 84 | Europe | Carfilzomib, Kyprolis, Lenalidomide, Revlimid, Dexamethasone | Fondazione EMN Italy Onlus | Multiple Myeloma, New Diagnosis Tumor | 01/26 | 01/26 | | |
| Recruiting | 3 | 357 | Europe, Japan, US, RoW | Belantamab mafodotin, Pomalidomide, Dexamethasone, Bortezomib | GlaxoSmithKline | Multiple Myeloma | 01/24 | 05/29 | | |
|
|
|
|
|
|
|
|
|
|
|
|
|
NCT03731234: Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance |
|
|
| Active, not recruiting | 2 | 75 | Europe | Ibrutinib, IMBRUVICA (commercial name) | Fondazione Italiana Linfomi - ETS, Janssen-Cilag S.p.A. | DLBCL | 07/24 | 07/27 | | |
| Terminated | 2 | 37 | Europe | Copanlisib, ALIQOPA | Fondazione Italiana Linfomi - ETS | Diffuse Large B-cell Lymphoma | 12/24 | 12/24 | | |
| Completed | 2 | 72 | Europe | Rituximab, Methotrexate, Procarbazine, Lenalidomide, Radiotherapy, Temozolomide | International Extranodal Lymphoma Study Group (IELSG) | Primary Central Nervous System Lymphoma | 12/24 | 12/24 | | |
NCT06588478: A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
|
|
| Recruiting | 2 | 249 | Europe, Canada, US, RoW | Pirtobrutinib | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 06/28 | 12/28 | | |
| Recruiting | 1 | 144 | Europe, Canada, US, RoW | Belantamab mafodotin, Bortezomib, Lenalidomide, Dexamethasone | GlaxoSmithKline | Multiple Myeloma | 11/24 | 06/25 | | |
|
| Recruiting | N/A | 343 | Europe, RoW | Questionnaire | Gruppo Italiano Malattie EMatologiche dell'Adulto, European Organisation for Research and Treatment of Cancer - EORTC | Acute Myeloid Leukemia | 06/21 | 12/22 | | |
IELSG37, NCT01599559: Randomized, Open-label, Two-arms, Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma |
|
|
| Active, not recruiting | N/A | 540 | Europe, Canada, US, RoW | observation, 3D-Conformal Radiotherapy (3D-CRT) | International Extranodal Lymphoma Study Group (IELSG) | Primary Mediastinal B-cell Lymphoma | 06/22 | 12/29 | | |
NCT04352556: COVID19-hematological Malignancies: the Italian Hematology Alliance |
|
|
| Recruiting | N/A | 250 | Europe | | Ospedale di Circolo - Fondazione Macchi | SARS-CoV-2 Infection, Hematological Malignancies | 10/22 | 10/22 | | |
| Recruiting | N/A | 1900 | Europe | Observation | Fondazione EMN Italy Onlus | Multiple Myeloma | 03/24 | 03/24 | | |
